Physician profile
Stephen D Hull
NPI 1831578558
$6,664.86
in general payments reported to CMS, 2019-2025
26 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $476 · 2021: $867 · 2022: $1,295 · 2023: $1,198 · 2024: $1,325 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,336.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,764.15 | 2019-2024 | Xarelto |
| Pfizer INC. | $751.26 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $676.01 | 2019-2025 | Ultomiris, Soliris |
| Inari Medical, INC. | $664.17 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $600.35 | 2019-2024 | |
| Abbvie INC. | $393.45 | 2021-2025 | |
| Gilead Sciences, INC. | $230.62 | 2021-2025 | Veklury |
| Lilly USA, LLC | $221.92 | 2024-2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $215.77 | 2019-2025 | Eliquis |
| Allergan, INC. | $170.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $163.45 | 2020-2023 | Lokelma |
| Livanova USA, INC. | $130.35 | 2023 | Tandemlife |
| Abbott Laboratories | $122.99 | 2022 | |
| Boston Scientific Corporation | $111.62 | 2022 | |
| Melinta Therapeutics, LLC | $100.30 | 2021-2025 | Orbactiv, Kimyrsa, Rezzayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $79.55 | 2024-2025 | Rybelsus, Ozempic |
| Impulse Dynamics (USA) INC. | $61.46 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.38 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $26.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.74 | 2023 | Jardiance |
| Genzyme Corporation | $18.25 | 2020 | |
| Amgen INC. | $18.13 | 2025 | Repatha |
| Chiesi USA, INC. | $17.07 | 2023 | Cleviprex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2023 | Xifaxan |
| Cvrx, INC. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.